We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer .
- Authors
So, Alan I.; Kim Chi; Danielson, Brita; Fleshner, Neil E.; Kinnaird, Adam; Kapoor, Anil; Niazi, Tamim; Pouliot, Fréderic; Rendon, Ricardo A.; Shayegan, Bobby; Sridhar, Srikala S.; Vigneault, Eric; Saad, Fred
- Abstract
The article presents the discussion on metastatic prostate cancer remaining an incurable disease. Topics include men with metastatic PCa having a poor prognosis with an estimated median overall survival (OS) of approximately 3–4 years; and practice-changing trials demonstrating improved survival in men with metastatic castration-naive/castration-sensitive prostate cancer.
- Subjects
CANADA; OSTEOPOROSIS prevention; PROSTATE tumors treatment; THERAPEUTIC use of antineoplastic agents; NONPROFIT organizations; BIOPSY; CLINICAL trials; ANTIANDROGENS; ALENDRONATE; RADICAL prostatectomy; ABIRATERONE acetate; ANTINEOPLASTIC agents; MONOCLONAL antibodies; METASTASIS; MEDICAL protocols; TUMOR classification; RADIONUCLIDE imaging; RISK assessment; CANCER patients; VITAMIN D; DIETARY supplements; ZOLEDRONIC acid; DOCETAXEL; SURVIVAL analysis (Biometry); HEALTH care teams; PROFESSIONAL associations; COMPUTED tomography; PREDNISONE; CALCIUM; PROSTATE tumors
- Publication
Canadian Urological Association Journal, 2022, Vol 16, Issue 12, pE581
- ISSN
1911-6470
- Publication type
Article
- DOI
10.5489/cuaj.8148